Copyright
©The Author(s) 2023.
World J Gastrointest Endosc. Jun 16, 2023; 15(6): 480-490
Published online Jun 16, 2023. doi: 10.4253/wjge.v15.i6.480
Published online Jun 16, 2023. doi: 10.4253/wjge.v15.i6.480
Risk factor | EC1 patients,n = 177 | Matched controls, n = 247 | P value |
Age (yr) | 65.00 | 63.17 | 0.637 |
BMI1 (kg/m2) | 24.48 | 26.29 | 0.003 |
Gender | 0.564 | ||
Female | 91 (51.40) | 134 (54.30) | |
Male | 86 (48.60) | 113 (45.70) | |
Race and ethnicity | 0.104 | ||
White | 74 (41.80) | 127 (51.40) | |
Black | 90 (50.80) | 109 (44.10) | |
Other1 | 13 (7.30) | 11 (4.50) | |
Heavy alcohol use | 16 (9.00) | 42 (17.00) | 0.019 |
Tobacco use | 97 (54.80) | 123 (49.80) | 0.309 |
GERD1 | 71 (40.10) | 68 (27.50) | 0.006 |
Diabetes | 63 (35.60) | 71 (28.70) | 0.135 |
Liver cirrhosis | 9 (5.10) | 7 (2.80) | 0.23 |
End stage renal disease | 24 (13.60) | 26 (10.60) | 0.347 |
Transplant recipient | 19 (10.70) | 5 (2.00) | < 0.001 |
Active Malignancy | 32 (18.10) | 32 (13.00) | 0.146 |
Immunosuppressive medication use1 | 32 (18.10) | 20 (8.10) | 0.002 |
TNF inhibitor use1 | 1 (0.60) | 1 (0.40) | 0.812 |
Proton pump inhibitor use | 85 (48.00) | 74 (30.00) | < 0.001 |
H2RA use | 21 (11.90) | 30 (12.10) | 0.93 |
Corticosteroid use | 62 (35.00) | 42 (17.00) | < 0.001 |
Tylenol use | 45 (25.40) | 40 (16.20) | 0.019 |
NSAID use1 | 18 (10.20) | 21 (8.50) | 0.558 |
Aspirin use | 69 (39.00) | 68 (27.50) | 0.013 |
Bisphosphonate use | 3 (1.70) | 2 (0.80) | 0.405 |
Antibiotic use | 22 (12.40) | 19 (7.70) | 0.104 |
Presenting symptom | EC1 patients, n = 177 | Matched controls, n = 247 |
Dysphagia | 52 (16.94) | 52 (11.95) |
Nausea | 46 (14.98) | 76 (17.47) |
Melena | 45 (14.66) | 58 (13.33) |
Vomiting | 42 (13.68) | 79 (18.16) |
Hematemesis | 26 (8.47) | 44 (10.11) |
Epigastric pain | 21 (6.84) | 22 (5.06) |
Weight loss | 18 (5.86) | 8 (1.84) |
Non-specific | 17 (5.54) | 36 (8.28) |
Abdominal pain | ||
Diarrhea | 13 (4.23) | 7 (1.61) |
Chest pain | 12 (3.91) | 18 (4.14) |
Asymptomatic | 11 (3.58) | 11 (2.53) |
Odynophagia | 10 (3.26) | 11 (2.53) |
Dyspepsia | 6 (1.95) | 9 (2.07) |
Acid reflux | 5 (1.63) | 2 (0.46) |
Unknown | 0 (0.00) | 2 (0.46) |
Risk factor | Odds ratio | P value |
Gender | ||
Female | Reference | |
Male | 1.28 | 0.269 |
Race and ethnicity | ||
White | Reference | |
Black | 1.50 | 0.080 |
Other1 | 2.55 | 0.041 |
Age | 1.00 | 0.720 |
BMI1 | 0.99 | 0.209 |
Heavy alcohol use | 0.51 | 0.059 |
GERD1 | 1.60 | 0.051 |
Transplant recipient | 5.81 | 0.009 |
Immunosuppressive medication use1 | 0.87 | 0.746 |
Proton pump inhibitor use | 1.66 | 0.030 |
Corticosteroid use | 2.05 | 0.007 |
Tylenol use | 1.57 | 0.092 |
Aspirin use | 1.45 | 0.115 |
- Citation: Kimchy AV, Ahmad AI, Tully L, Lester C, Sanghavi K, Jennings JJ. Prevalence and clinical risk factors for esophageal candidiasis in non-human immunodeficiency virus patients: A multicenter retrospective case-control study. World J Gastrointest Endosc 2023; 15(6): 480-490
- URL: https://www.wjgnet.com/1948-5190/full/v15/i6/480.htm
- DOI: https://dx.doi.org/10.4253/wjge.v15.i6.480